Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -546K | 0 | 0 | 0 | 0 |
| Operating Income | -133M | -104M | -80M | -59M | -26M |
| EBITDA | -119M | -104M | -80M | -59M | -26M |
| Net Income | -120M | -86M | -69M | -55M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$28.32
-2.58% today
1Y Change
+177.96%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tyra Biosciences, Inc. (TYRA) is a Healthcare stock with a market cap of $1.83B and listed on NASDAQ. The stock last traded around $28.32 and up 178.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -33.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -33.1%, free cash flow -35.3% with operating margin 0.0% and ROIC -50.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TYRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TYRA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TYRA Max Drawdown
-35.82%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TYRA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$26.3M
+52.5% YoY
Free Cash Flow
-$24.4M
+52.0% YoY
Revenue Growth
+0.0%
EPS Growth
-33.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -546K | 0 | 0 | 0 | 0 |
| Operating Income | -133M | -104M | -80M | -59M | -26M |
| EBITDA | -119M | -104M | -80M | -59M | -26M |
| Net Income | -120M | -86M | -69M | -55M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77M | 92M | 58M | 251M | 302M |
| Total Assets | 283M | 364M | 226M | 266M | 307M |
| Total Liabilities | 23M | 20M | 22M | 8M | 5M |
| Shareholder Equity | 259M | 343M | 204M | 258M | 302M |
| Total Debt | 6M | 6M | 6M | 3M | 1M |
| Net Debt | -72M | -86M | -52M | -249M | -301M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
+52.8% YoY
Capital Expenditures
661K
-18.2% YoY
Free Cash Flow
24M
+52.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-41.2%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.